Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mammography | 23 | 2022 | 77 | 7.320 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 15 | 2019 | 58 | 5.720 |
Why?
|
Breast Neoplasms | 22 | 2022 | 441 | 5.710 |
Why?
|
Image Interpretation, Computer-Assisted | 14 | 2019 | 107 | 3.910 |
Why?
|
Algorithms | 20 | 2022 | 419 | 3.280 |
Why?
|
Diagnosis, Computer-Assisted | 6 | 2022 | 57 | 2.910 |
Why?
|
Tomography, X-Ray Computed | 12 | 2022 | 465 | 2.720 |
Why?
|
Machine Learning | 7 | 2022 | 79 | 1.830 |
Why?
|
Pattern Recognition, Automated | 8 | 2016 | 32 | 1.800 |
Why?
|
ROC Curve | 14 | 2022 | 137 | 1.640 |
Why?
|
Breast | 6 | 2022 | 51 | 1.610 |
Why?
|
Image Processing, Computer-Assisted | 8 | 2022 | 246 | 1.450 |
Why?
|
Retrospective Studies | 18 | 2022 | 2444 | 1.340 |
Why?
|
Ovarian Neoplasms | 7 | 2021 | 563 | 1.210 |
Why?
|
Humans | 56 | 2022 | 26856 | 1.150 |
Why?
|
Support Vector Machine | 6 | 2022 | 21 | 1.130 |
Why?
|
Abdominal Fat | 2 | 2017 | 17 | 1.110 |
Why?
|
Drug Monitoring | 2 | 2016 | 34 | 1.030 |
Why?
|
Female | 33 | 2022 | 14462 | 0.970 |
Why?
|
Subarachnoid Hemorrhage | 2 | 2022 | 54 | 0.900 |
Why?
|
Antineoplastic Agents | 3 | 2016 | 656 | 0.800 |
Why?
|
Magnetic Resonance Imaging | 2 | 2016 | 802 | 0.760 |
Why?
|
Chromosomes, Human | 7 | 2013 | 31 | 0.740 |
Why?
|
Stomach Neoplasms | 1 | 2021 | 19 | 0.730 |
Why?
|
Radiography, Thoracic | 1 | 2020 | 12 | 0.730 |
Why?
|
Peritoneal Neoplasms | 1 | 2021 | 76 | 0.690 |
Why?
|
Microscopy | 4 | 2022 | 38 | 0.680 |
Why?
|
Feasibility Studies | 6 | 2019 | 187 | 0.680 |
Why?
|
Phantoms, Imaging | 10 | 2022 | 96 | 0.670 |
Why?
|
Metaphase | 6 | 2014 | 29 | 0.670 |
Why?
|
Middle Aged | 15 | 2022 | 6825 | 0.660 |
Why?
|
Aged | 14 | 2021 | 5169 | 0.660 |
Why?
|
Karyotyping | 5 | 2013 | 24 | 0.650 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2019 | 31 | 0.650 |
Why?
|
Hyperthermia, Induced | 1 | 2019 | 30 | 0.640 |
Why?
|
Area Under Curve | 6 | 2022 | 94 | 0.640 |
Why?
|
Colon | 1 | 2019 | 119 | 0.610 |
Why?
|
Mammary Glands, Human | 2 | 2017 | 18 | 0.600 |
Why?
|
Colonic Neoplasms | 1 | 2019 | 117 | 0.590 |
Why?
|
Adenocarcinoma | 1 | 2019 | 284 | 0.540 |
Why?
|
Risk Assessment | 2 | 2018 | 586 | 0.530 |
Why?
|
Pancreatic Neoplasms | 1 | 2022 | 505 | 0.510 |
Why?
|
Biomarkers | 2 | 2019 | 731 | 0.510 |
Why?
|
Breast Diseases | 1 | 2015 | 7 | 0.510 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 102 | 0.480 |
Why?
|
Breast Density | 4 | 2019 | 10 | 0.450 |
Why?
|
Models, Biological | 2 | 2015 | 446 | 0.430 |
Why?
|
Prognosis | 5 | 2022 | 758 | 0.410 |
Why?
|
Lung Neoplasms | 1 | 2016 | 339 | 0.400 |
Why?
|
Disease-Free Survival | 3 | 2016 | 225 | 0.380 |
Why?
|
X-Rays | 6 | 2022 | 29 | 0.360 |
Why?
|
Treatment Outcome | 6 | 2021 | 2267 | 0.360 |
Why?
|
Aged, 80 and over | 5 | 2019 | 1927 | 0.350 |
Why?
|
Adult | 8 | 2021 | 7389 | 0.340 |
Why?
|
Subcutaneous Fat | 2 | 2021 | 16 | 0.330 |
Why?
|
Intra-Abdominal Fat | 2 | 2021 | 20 | 0.330 |
Why?
|
Tumor Burden | 3 | 2019 | 108 | 0.330 |
Why?
|
High-Throughput Screening Assays | 3 | 2014 | 36 | 0.320 |
Why?
|
Reproducibility of Results | 7 | 2017 | 748 | 0.320 |
Why?
|
Sensitivity and Specificity | 5 | 2017 | 509 | 0.310 |
Why?
|
Lenses | 2 | 2022 | 12 | 0.300 |
Why?
|
Image Enhancement | 4 | 2016 | 57 | 0.300 |
Why?
|
Diabetes Mellitus | 2 | 2020 | 207 | 0.290 |
Why?
|
Contrast Media | 2 | 2018 | 93 | 0.290 |
Why?
|
Adipose Tissue | 2 | 2019 | 179 | 0.270 |
Why?
|
Microscopy, Fluorescence | 3 | 2013 | 161 | 0.270 |
Why?
|
Early Detection of Cancer | 2 | 2018 | 121 | 0.270 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 36 | 0.260 |
Why?
|
Biomarkers, Tumor | 2 | 2021 | 377 | 0.260 |
Why?
|
Datasets as Topic | 2 | 2015 | 21 | 0.240 |
Why?
|
Signal Processing, Computer-Assisted | 3 | 2018 | 68 | 0.240 |
Why?
|
Cadmium Compounds | 2 | 2022 | 6 | 0.240 |
Why?
|
Radiographic Image Enhancement | 3 | 2021 | 28 | 0.230 |
Why?
|
Logistic Models | 2 | 2016 | 397 | 0.230 |
Why?
|
Pilot Projects | 2 | 2022 | 391 | 0.220 |
Why?
|
Bevacizumab | 2 | 2021 | 93 | 0.220 |
Why?
|
Thrombectomy | 2 | 2020 | 26 | 0.210 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2020 | 277 | 0.210 |
Why?
|
Cytidine Triphosphate | 1 | 2022 | 2 | 0.200 |
Why?
|
Quantum Dots | 1 | 2022 | 6 | 0.200 |
Why?
|
Photons | 2 | 2022 | 27 | 0.200 |
Why?
|
Computed Tomography Angiography | 1 | 2022 | 24 | 0.200 |
Why?
|
Hydrocephalus | 1 | 2022 | 51 | 0.190 |
Why?
|
Hyperglycemia | 1 | 2022 | 77 | 0.190 |
Why?
|
Risk Factors | 2 | 2018 | 2017 | 0.180 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2021 | 38 | 0.180 |
Why?
|
Equipment Design | 6 | 2018 | 211 | 0.170 |
Why?
|
Survival Analysis | 2 | 2021 | 277 | 0.170 |
Why?
|
Carotid Artery Thrombosis | 1 | 2019 | 4 | 0.170 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2019 | 16 | 0.170 |
Why?
|
Time-to-Treatment | 1 | 2019 | 26 | 0.170 |
Why?
|
Chromosomes | 2 | 2022 | 59 | 0.160 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 1 | 2019 | 10 | 0.160 |
Why?
|
Endovascular Procedures | 1 | 2019 | 60 | 0.160 |
Why?
|
User-Computer Interface | 1 | 2019 | 38 | 0.160 |
Why?
|
Smokers | 1 | 2020 | 123 | 0.160 |
Why?
|
Aneurysm | 1 | 2019 | 25 | 0.160 |
Why?
|
Doxorubicin | 1 | 2019 | 74 | 0.160 |
Why?
|
Lymphocytes | 1 | 2019 | 83 | 0.160 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 290 | 0.150 |
Why?
|
Drug Carriers | 1 | 2019 | 109 | 0.150 |
Why?
|
Ultrasonography | 1 | 2019 | 228 | 0.150 |
Why?
|
Spectrometry, X-Ray Emission | 2 | 2018 | 12 | 0.150 |
Why?
|
Predictive Value of Tests | 3 | 2014 | 472 | 0.150 |
Why?
|
Brain Ischemia | 1 | 2019 | 80 | 0.150 |
Why?
|
Microbubbles | 1 | 2017 | 5 | 0.150 |
Why?
|
Artificial Intelligence | 2 | 2009 | 43 | 0.150 |
Why?
|
Abdomen | 1 | 2017 | 41 | 0.140 |
Why?
|
Imaging, Three-Dimensional | 1 | 2017 | 128 | 0.140 |
Why?
|
Blood Platelets | 1 | 2019 | 203 | 0.140 |
Why?
|
Odds Ratio | 2 | 2014 | 231 | 0.140 |
Why?
|
Drug Therapy | 1 | 2016 | 15 | 0.140 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2017 | 40 | 0.140 |
Why?
|
Risk | 1 | 2016 | 133 | 0.130 |
Why?
|
Quality Control | 1 | 2016 | 20 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2016 | 108 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 367 | 0.130 |
Why?
|
X-Ray Microtomography | 1 | 2016 | 31 | 0.130 |
Why?
|
Nanoparticles | 1 | 2019 | 273 | 0.120 |
Why?
|
Radiology | 1 | 2015 | 20 | 0.120 |
Why?
|
False Positive Reactions | 1 | 2014 | 29 | 0.120 |
Why?
|
Confidence Intervals | 1 | 2014 | 66 | 0.110 |
Why?
|
Young Adult | 2 | 2019 | 2584 | 0.110 |
Why?
|
Disease Models, Animal | 1 | 2019 | 1394 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2016 | 309 | 0.110 |
Why?
|
Chromosome Banding | 1 | 2013 | 5 | 0.110 |
Why?
|
Time Factors | 2 | 2014 | 1564 | 0.110 |
Why?
|
Neoplasms | 1 | 2021 | 756 | 0.110 |
Why?
|
Cytogenetic Analysis | 1 | 2012 | 8 | 0.100 |
Why?
|
Neoplasm Staging | 1 | 2014 | 457 | 0.100 |
Why?
|
Gold | 1 | 2014 | 129 | 0.100 |
Why?
|
Mice | 2 | 2019 | 4402 | 0.100 |
Why?
|
Chromosome Mapping | 1 | 2012 | 131 | 0.100 |
Why?
|
Animals | 4 | 2019 | 9954 | 0.100 |
Why?
|
Metal Nanoparticles | 1 | 2014 | 128 | 0.100 |
Why?
|
Artifacts | 1 | 2012 | 49 | 0.100 |
Why?
|
Databases, Factual | 3 | 2019 | 252 | 0.090 |
Why?
|
Tellurium | 2 | 2022 | 6 | 0.090 |
Why?
|
Adiposity | 2 | 2021 | 87 | 0.080 |
Why?
|
Papanicolaou Test | 1 | 2009 | 24 | 0.080 |
Why?
|
Vaginal Smears | 1 | 2009 | 44 | 0.080 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2009 | 72 | 0.080 |
Why?
|
Male | 3 | 2019 | 12866 | 0.070 |
Why?
|
Signal-To-Noise Ratio | 2 | 2018 | 16 | 0.070 |
Why?
|
Centromere | 1 | 2008 | 38 | 0.070 |
Why?
|
Prospective Studies | 2 | 2022 | 1219 | 0.070 |
Why?
|
Computers | 1 | 2006 | 29 | 0.070 |
Why?
|
Equipment Failure Analysis | 2 | 2017 | 36 | 0.060 |
Why?
|
DNA | 1 | 2006 | 365 | 0.060 |
Why?
|
Supervised Machine Learning | 1 | 2022 | 8 | 0.050 |
Why?
|
Blood Volume | 1 | 2022 | 8 | 0.050 |
Why?
|
Fourier Analysis | 1 | 2022 | 31 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2022 | 63 | 0.050 |
Why?
|
Mastectomy | 1 | 2021 | 21 | 0.050 |
Why?
|
Cerebral Hemorrhage | 1 | 2022 | 90 | 0.050 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2020 | 28 | 0.050 |
Why?
|
Infarction | 1 | 2020 | 8 | 0.040 |
Why?
|
Lymphatic Metastasis | 1 | 2020 | 119 | 0.040 |
Why?
|
Lymph Nodes | 1 | 2020 | 95 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2021 | 399 | 0.040 |
Why?
|
Child | 1 | 2006 | 2152 | 0.040 |
Why?
|
Cerebral Infarction | 1 | 2019 | 26 | 0.040 |
Why?
|
Carotid Artery, Internal | 1 | 2019 | 19 | 0.040 |
Why?
|
Middle Cerebral Artery | 1 | 2019 | 48 | 0.040 |
Why?
|
Mean Platelet Volume | 1 | 2019 | 4 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 213 | 0.040 |
Why?
|
Regression Analysis | 1 | 2019 | 209 | 0.040 |
Why?
|
Angiogenesis Inhibitors | 1 | 2019 | 104 | 0.040 |
Why?
|
Tissue Array Analysis | 1 | 2018 | 24 | 0.040 |
Why?
|
Platelet Count | 1 | 2019 | 112 | 0.040 |
Why?
|
Cluster Analysis | 1 | 2018 | 114 | 0.040 |
Why?
|
Sex Factors | 1 | 2019 | 445 | 0.040 |
Why?
|
Calibration | 1 | 2018 | 28 | 0.040 |
Why?
|
Age Factors | 1 | 2019 | 716 | 0.040 |
Why?
|
Miniaturization | 1 | 2017 | 10 | 0.040 |
Why?
|
Filtration | 1 | 2016 | 8 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2016 | 53 | 0.030 |
Why?
|
Plastics | 1 | 2015 | 5 | 0.030 |
Why?
|
Chickens | 1 | 2015 | 59 | 0.030 |
Why?
|
Fishes | 1 | 2015 | 31 | 0.030 |
Why?
|
Inflammation | 1 | 2019 | 598 | 0.030 |
Why?
|
Radiography | 1 | 2015 | 200 | 0.030 |
Why?
|
Bone and Bones | 1 | 2015 | 74 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 647 | 0.030 |
Why?
|
Automation, Laboratory | 1 | 2013 | 4 | 0.030 |
Why?
|
Workflow | 1 | 2013 | 22 | 0.030 |
Why?
|
Task Performance and Analysis | 1 | 2013 | 37 | 0.030 |
Why?
|
Computer Simulation | 1 | 2014 | 221 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2013 | 981 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 578 | 0.020 |
Why?
|
Decision Trees | 1 | 2008 | 7 | 0.020 |
Why?
|
Models, Genetic | 1 | 2008 | 123 | 0.020 |
Why?
|
Leukemia | 1 | 2008 | 22 | 0.020 |
Why?
|
Software | 1 | 2008 | 121 | 0.020 |
Why?
|